Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen income Statement — Total revenues ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Income (DB)
Latest, FY2025
36,751
Period ended Dec 31, 2025
Change on a year earlier
+10.0%
33,424 in FY2024
History
19 years
Since FY2007
Sources
17
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Income Statement — Total revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 36,751 | +10.0% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 33,424 | +18.6% | Form 10-K (filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 28,190 | +7.1% | Form 10-K (filed 2024-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 26,323 | +1.3% | Form 10-K (filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 25,979 | +2.2% | Form 10-K (filed 2022-02-16) ↗ |
| FY2020 | Dec 31, 2020 | 25,424 | +8.8% | Form 10-K (filed 2021-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 23,362 | -1.6% | Form 10-K (filed 2020-02-12) ↗ |
| FY2018 | Dec 31, 2018 | 23,747 | +3.9% | Form 10-K (filed 2019-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 22,849 | -0.6% | Form 10-K (filed 2018-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 22,991 | +6.1% | Form 10-K (filed 2017-02-14) ↗ |
| FY2015 | Dec 31, 2015 | 21,662 | +8.0% | Form 10-K (filed 2016-02-16) ↗ |
| FY2014 | Dec 31, 2014 | 20,063 | +7.4% | Form 10-K (filed 2015-02-19) ↗ |
| FY2013 | Dec 31, 2013 | 18,676 | +8.2% | Form 10-K (filed 2014-02-24) ↗ |
| FY2012 | Dec 31, 2012 | 17,265 | +10.8% | Form 10-K (filed 2013-02-27) ↗ |
| FY2011 | Dec 31, 2011 | 15,582 | +3.5% | Form 10-K (filed 2012-02-29) ↗ |
| FY2010 | Dec 31, 2010 | 15,053 | +2.8% | Form 10-K (filed 2011-02-25) ↗ |
| FY2009 | Dec 31, 2009 | 14,642 | -2.4% | Form 10-K (filed 2010-03-01) ↗ |
| FY2008 | Dec 31, 2008 | 15,003 | +1.6% | Form 10-K (filed 2010-03-01) ↗ |
| FY2007 | Dec 31, 2007 | 14,771 | – | Form 10-K (filed 2010-03-01) ↗ |
Breakdown
What makes up income statement — total revenues ($m)
- Cost of sales ($M)12,037 · FY2025
- Research and development expense ($M)7,272 · FY2025
- Selling, general and administrative expense ($M)7,050 · FY2025
- Advertising expense ($M)963 · FY2025
- Impairment charges ($M)-111 · FY2015
- Restructuring charges ($M)267 · FY2023
- Total operating expenses ($M)27,671 · FY2025
- Operating income ($M)9,080 · FY2025
- Interest expense, net ($M)2,755 · FY2025
- Interest and other income, net ($M)408 · FY2025
- Other nonoperating income (expense) ($M)2,651 · FY2025
- Income before income taxes ($M)8,976 · FY2025
- Provision for income taxes ($M)1,265 · FY2025
- Net income ($M)7,711 · FY2025
- Earnings per share — Basic ($/sh)14.33 · FY2025
- Earnings per share — Diluted ($/sh)14.23 · FY2025
- Weighted-average basic shares (M)538 · FY2025
- Weighted-average diluted shares (M)542 · FY2025
- Dividends declared per share ($/sh)9.66 · FY2025
Cite this data
StockData. (2026). Amgen Income Statement — Total revenues ($M) ($M), annual FY2007–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/fs_income_stmt
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.